logo
Share SHARE
FONT-SIZE Plus   Neg

GlaxoSmithKline Receives FDA Approval For PROMACTA

GlaxoSmithKline plc (GSK) Monday said the U.S. Food and Drug Administration has approved PROMACTA for the treatment of low blood platelet counts in patients with chronic hepatitis C.

PROMACTA is the first supportive care treatment available to patients who are ineligible for interferon-based therapy due to their low blood platelet counts.

The approval for PROMACTA was based on results from ENABLE 1 and 2, a two Phase III randomized, double-blind, placebo-controlled, multicenter studies, which collectively enrolled 1,521 patients with lower platelet counts.

"Some chronic hepatitis C patients suffer from low blood platelet counts. Commonly prescribed interferon-based therapies can worsen the problem of low blood platelet counts. Today's FDA approval of PROMACTA gives doctors a tool to address the low platelet challenge, " said Paolo Paoletti, M.D., President, GlaxoSmithKline Oncology.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of UBS AG were losing around 5 percent in the morning trading after the Swiss financial services giant reported Tuesday sharply lower profit in its first quarter amid lower net fee and commission as well as trading income. Net interest income, however, improved from last year. Looking ahead, the company said that the ongoing underlying macroeconomic challenges and geopolitical risks ... Asia-focused lender HSBC Holdings Plc reported Tuesday a decline in the first-quarter profit, on weak revenues and net interest income. The results reflected weak performance in all segments and business regions, except Middle East and North Africa as well as CMB. An Illinois woman has filed a lawsuit against Starbucks accusing that the coffee retail giant is misleading customers by "underfilling" its cold beverages. According to the plaintiff, Starbucks is cheating customers by serving cold coffees with too much ice cubes and less coffee than advertised, "often...
comments powered by Disqus
Follow RTT